Vivos Therapeutics Inc (NASDAQ:VVOS) traded at $4.00 at close of the session on current trade day and made a downward move of -5.88% on its previous day’s price.
Looking at the stock we see that its previous close was $4.25 and the beta (5Y monthly) reads 7.433 with the day’s price range being $3.9171 – $4.267. In terms of its 52-week price range, VVOS has a high of $6.28 and a low of $1.91. The company’s stock has lost about -21.88% over that past 30 days.
Vivos Therapeutics Inc has a market cap of $23.56 million and is expected to release its quarterly earnings report in March.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 3.89M, with a low of 3.87M and a high of 3.9M. The median projection represents growth squeezing down to 19.62% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 15.2M, or 10.15% up from figures reported last year.
On the other hand, looking at the outlook for the VVOS stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Buy.
Looking further, we note the current price level is -7.46% off its SMA20 and -10.99% from its 50-day simple moving average. The RSI (14) is pointing at 44.60 while the volatility over the past week is 7.13% and jumps to 9.27% over the past one month. The beta value is 7.43, while the average true range (ATR) is currently pointing at 0.39.
Coming back to Vivos Therapeutics Inc (NASDAQ:VVOS), we note that the average 3-month trading volume was 242.42K, while that of the preceding 10-day period stands at 0.12 million. Current shares outstanding are 4.77 million.
The insiders hold 22.02% of the company’s shares while institutions hold 12.19%. The data shows that short shares as of 2025-01-31, stood at 0.28 million at a short ratio of 0.9. This represents a 480.00 short interest in shares outstanding on 2025-01-31. Shares short rose in January from the previous month at 0.12 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -6.76% down in year-to-date price movement.
